// App-Quantinova.ai

SAT-1032 : Successful Treatment of a Patient with Extreme Insulin Resistance Due to High Levels of Insulin Receptor Autoantibodies (Type B Insulin Resistance) with Rituximab

Researchers

Presenter

  • Lars C Moeller

Principal Investigators

  • Emmanouil-Dimitrios Manikas

  • Iona Isaac

  • Rana Malek

  • Robert Kenneth Semple

  • Dagmar Fuehrer

Medical Centers

  • University of Maryland School of Medicine, Baltimore, MD

  • University of Duisburg-Essen, Essen, Germany

  • University of Cambridge, Cambridge, United Kingdom

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Acanthosis Nigricans

  • Diabetes

  • Obesity

Biomarkers

  • Hemoglobin A1c

  • Insulin

Drug/Treatment

  • Insulin glargine

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Prandial Insulin

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved